Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: The xelbevoct study

Alfredo Berruti, Nicola Fazio, Anna Ferrero, Maria P. Brizzi, Marco Volante, Elisabetta Nobili, Lucia Tozzi, Lisa Bodei, Mirella Torta, Antonio D'Avolio, Adriano M. Priola, Nadia Birocco, Vito Amoroso, Guido Biasco, Mauro Papotti, Luigi Dogliotti

Research output: Contribution to journalArticlepeer-review

Abstract

Background: We assessed the activity and toxicity of the XELBEVOCT regimen in patients with metastatic well-to-moderately differentiated neuroendocrine neoplasms (WMD-NEN). Ancillary studies evaluated hypertension, proteinuria, and vascular endothelial growth factor (VEGF) polymorphisms in predicting progression-free survival (PFS) and the predictive role of serum vitamin D in progression-free survival and proteinuria onset.Methods: This prospective phase 2 study included 45 patients with WMD-NEN arising from various primary sites. The treatment regimen was octreotide long-acting release (LAR), 20 mg monthly, metronomic capecitabine, 2000 mg/daily, and intravenous bevacizumab, 5 mg/kg every 2 weeks, without interruption for 9 months. Bevacizumab was continued until disease progression.Results: Partial response was obtained in 8 patients (17.8%, 95% confidence interval [CI], 6.4%-28.2%); tumor response was more frequent in pancreatic than in non-pancreatic malignancies. The median PFS was 14.9 months; median overall survival was not attained. Biochemical and symptomatic responses were observed in 52.9% and 82.3% of cases, respectively. The treatment was well tolerated. Grade 3 toxicities included hand and foot syndrome (11.1%), proteinuria (4.4%), and renal toxicity (2.2%). Proteinuria (all grades) was correlated with longer PFS (p = 0.017). There was an inverse relationship between proteinuria and vitamin D levels. VEGF polymorphisms were not associated with patient outcome.Conclusion: The XELBEVOCT regimen is active and well tolerated in patients with metastatic WMD-NEN. Proteinuria correlated with hypovitaminosis D status and was the best predictive factor of treatment efficacy.Trial registration: Trial registration number NCT01203306.

Original languageEnglish
Article number184
JournalBMC Cancer
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 14 2014

Keywords

  • Bevacizumab
  • Capecitabine
  • Octreotide
  • Pancreatic endocrine tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics
  • Medicine(all)

Fingerprint Dive into the research topics of 'Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: The xelbevoct study'. Together they form a unique fingerprint.

Cite this